Cullinan Oncology goes full circle, scoring $275M for sharing the load on EGFR inhibitor with original developer
Only a few months after CEO Nadim Ahmed came over from Bristol Myers Squibb and joined as the top brass at the cancer-focused biotech Cullinan Oncology, the second half of a major deal has finally clicked into place — giving Cullinan a well-timed $275 million.
The Massachusetts biotech announced early Thursday morning that it has completed Part II of a deal with Japanese biotech Taiho Pharmaceutical that originally started back in 2019 — culminating in a co-commercialization and co-development partnership for CLN-081, a tyrosine kinase inhibitor candidate being investigated for NSCLC with a specific type of mutation already pursued by at least two pharma giants: EGFR exon 20.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,500+ biopharma pros reading Endpoints daily — and it's free.